Since we found that modification of TMEM16A expression affects migration and angiogenesis in HUVECs, and changing of TMEM16A expression can also influence the function of VEGF and AngII regarding the migration and angiogenesis, TMEM16A may become a new potential target on therapy of pathological angiogenesis forced diseases and ischemic diseases, when co-working with or without other agents. This evidence concerns the gene ANO1 and ischemic disease.